U.S. Food and Drug Administration Approves Bristol Myers Squibb's Zeposia® , an Oral Treatment for Adults with Moderately to Severely Active Ulcerative Colitis1
Zeposia the first and only oral sphingosine 1-phosphate receptor modulator approved for ulcerative colitis 1 represents a new way of treating this chronic immune-mediated disease 2 Zeposia demonstrated significant improvements across all primary and key secondary efficacy endpoints including clinical remission, clinical response, endoscopic improvement and endoscopic-histologic mucosal improvement versus placebo at ...